Pfizer Inc.

NYSE:PFE  
39.58
+0.38 (+0.98%)
4:03:58 PM EDT: $39.50 -0.08 (-0.19%)
Products, Regulatory

Pfizer Reports Positive Clinical Data for BCMA-CD3 Bispecific Antibody in Multiple Myeloma

Published: 12/07/2020 12:21 GMT
Pfizer Inc. (PFE) - Pfizer Reports Positive Clinical Data for Bcma-cd3 Bispecific Antibody (pf-06863135) in Multiple Myeloma.
Pfizer Inc - Data From 30 Patients With Relapsed Or Refractory Multiple Myeloma Showed Manageable Safety Across All Subcutaneous Dose Levels.
Pfizer Inc - Phase 1 Study Showed No Dose-limiting Toxicities Observed, 83% of Patients Achieved a Clinical Response at Highest Dose Level.